Human Metabolome Technologies (6090) · InitiativeReframed
Building a Framework for HMTバイオメディカル to Commercialize Biomarker Research
First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2021-Q2.
4entries
5years
0from disclosures
How it moved
Same theme, other companies
Expansion from Biomarker Research into Diagnostic Reagents and Epidemiology ServicesA theme 6 companies write about · 0 as a headwind · 12 as a tailwind
Human Metabolome Technologies moved to the "Worse" side of this theme in 2021.
0 other companies' latest entry also says "Reframed".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2021-Q2ReframedAnnual report
「Under this agreement, the company absorbed HMTバイオメディカル株式会社 in a merger effective 1 January 2021.」
The structure changed from one centered on the subsidiary HMTバイオメディカル to integration of the business into the parent company through the absorption-type merger effective 1 January 2021. - FY2020RestatedAnnual report
「The biomarker business is being developed primarily through HMT-B, which was established in January 2016.」
The company is reaffirming its operating structure for the biomarker business centered on HMTバイオメディカル. - FY2019RestatedAnnual report
「The biomarker business is being developed primarily through HMT-B, which was established in January 2016.」
The company reaffirmed the framework for the biomarker business centered on HMTバイオメディカル. - FY2017First statedAnnual report
「The biomarker business is being developed primarily through HMT-B, which was established in January 2016.」
The company established HMTバイオメディカル株式会社 and built a framework for developing the biomarker business centered on that company.